Prediction model and scores for 3 months MTX non-response (DAS28>3.2).
收藏NIAID Data Ecosystem2026-03-10 收录
数据链接：
官方服务：
资源简介：
Prediction model and scores for 3 months MTX non-response (DAS28>3.2).
应用场景：
创建时间：
2018-12-10
相关数据集
Table_2_Comparison of Efficacy of Acupuncture-Related Therapy in the Treatment of Rheumatoid Arthritis: A Network Meta-Analysis of Randomized Controlled Trials.docx
BackgroundThe refractory, repetitive, and disabling characteristic of rheumatoid arthritis (RA) has seriously influenced the patients’ quality of life, and makes it a major public health problem. As a
NIAID Data Ecosystem50
Additional file 7: of Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
Cell subsets related to miRNA expression level, as measured by OpenArray or qPCR assay. In this additional analysis, miRNA expression levels are compared with FACS results on PBMC cell subsets. (XLSX
Figshare2016-12-14 更新40
Table_1_Molecular signature of methotrexate response among rheumatoid arthritis patients.DOCX
BackgroundMethotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA), but failure of satisfying treatment response occurs in a significant proportion of patients. Here we present a l
NIAID Data Ecosystem20
Available IPD datapackage for study 'A Multicenter Randomized Placebo-Controlled Phase II Study of the Human Anti-TNF Antibody D2E7 Administered as Subcutenous Injections in Rheumatoid Arthritis Patients Treated with Methotrexate.'
Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promot
DataCite Commons2025-01-06 更新40
Dataset from A Phase IIIb Open-label run-in Double-blind, Placebo Controlled, Randomized Study to Evaluate the Safety/Efficacy of Certolizumab Pegol Administered Concomitantly With Stable-dose Methotrexate in Patients With Active Rheumatoid Arthritis.
During the run-in period, CZP will be administered at 400 mg (2 injections) at Wks 0, 2, and 4 and 200 mg with placebo (1 injection placebo, 1 injection CZP) at Wks 6, 8, 10, 12, 14 and 16. At Wk 18 p
NIAID Data Ecosystem20
